Literature DB >> 18501971

Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder.

Ixchel Herrera-Guzmán1, Esteve Gudayol-Ferré, Jennifer Lira-Mandujano, Jorge Herrera-Abarca, Daniel Herrera-Guzmán, Karina Montoya-Pérez, Joan Guardia-Olmos.   

Abstract

Cognitive effects of antidepressants and cognitive predictors of antidepressant treatment response are recent focuses of interest in the neuropsychology of depression. We studied the cognitive predictors of treatment response to bupropion and its neuropsychological effects in patients with major depressive disorder. Twenty subjects meeting the DSM-IV criteria for major depressive disorder were assessed with the Hamilton Depression Rating Scale and a neuropsychological battery. Subjects were medicated with 150 mg/day of bupropion sustained release for 8 weeks. At the end of the trial, 12 subjects were classified as responders to treatment and 8 were non-responders. Our findings suggest that low pretreatment measures of visual memory and low levels of mental processing speed are predictive of good response to bupropion. The cognitive effects of bupropion after the treatment showed that patients improved in visual memory measures and in mental processing speed. Our results suggest that cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder could be closely related. These findings need to be replicated due to the exploratory nature of the present work.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18501971     DOI: 10.1016/j.psychres.2007.04.012

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  23 in total

Review 1.  Psychomotor retardation in depression: biological underpinnings, measurement, and treatment.

Authors:  Jeylan S Buyukdura; Shawn M McClintock; Paul E Croarkin
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-10-31       Impact factor: 5.067

2.  Neuropsychological function before and after subcallosal cingulate deep brain stimulation in patients with treatment-resistant depression.

Authors:  Jared L Moreines; Shawn M McClintock; Mary E Kelley; Paul E Holtzheimer; Helen S Mayberg
Journal:  Depress Anxiety       Date:  2014-04-17       Impact factor: 6.505

Review 3.  Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years.

Authors:  G Voegeli; M L Cléry-Melin; N Ramoz; P Gorwood
Journal:  Drugs       Date:  2017-12       Impact factor: 9.546

4.  Pretreatment Reward Sensitivity and Frontostriatal Resting-State Functional Connectivity Are Associated With Response to Bupropion After Sertraline Nonresponse.

Authors:  Yuen-Siang Ang; Roselinde Kaiser; Thilo Deckersbach; Jorge Almeida; Mary L Phillips; Henry W Chase; Christian A Webb; Ramin Parsey; Maurizio Fava; Patrick McGrath; Myrna Weissman; Phil Adams; Patricia Deldin; Maria A Oquendo; Melvin G McInnis; Thomas Carmody; Gerard Bruder; Crystal M Cooper; Cherise R Chin Fatt; Madhukar H Trivedi; Diego A Pizzagalli
Journal:  Biol Psychiatry       Date:  2020-04-23       Impact factor: 13.382

5.  Bupropion increases activation in nucleus accumbens during anticipation of monetary reward.

Authors:  Yumiko Ikeda; Takuya Funayama; Amane Tateno; Haruhisa Fukayama; Yoshiro Okubo; Hidenori Suzuki
Journal:  Psychopharmacology (Berl)       Date:  2019-07-24       Impact factor: 4.530

6.  Treatment-related improvement in neuropsychological functioning in suicidal depressed patients: paroxetine vs. bupropion.

Authors:  Marianne Gorlyn; John Keilp; Ainsley Burke; Maria Oquendo; J John Mann; Michael Grunebaum
Journal:  Psychiatry Res       Date:  2014-12-13       Impact factor: 3.222

Review 7.  Neuropsychologic effects of neuromodulation techniques for treatment-resistant depression: a review.

Authors:  Jared L Moreines; Shawn M McClintock; Paul E Holtzheimer
Journal:  Brain Stimul       Date:  2010-02-11       Impact factor: 8.955

Review 8.  The role of dopaminergic agents in improving quality of life in major depressive disorder.

Authors:  Waguih William IsHak; Michael Davis; Jessica Jeffrey; Konstantin Balayan; Robert N Pechnick; Kara Bagot; Mark Hyman Rapaport
Journal:  Curr Psychiatry Rep       Date:  2009-12       Impact factor: 5.285

9.  Neurocognitive predictors of antidepressant clinical response.

Authors:  Gerard E Bruder; Jorge E Alvarenga; Daniel Alschuler; Karen Abraham; John G Keilp; David J Hellerstein; Jonathan W Stewart; Patrick J McGrath
Journal:  J Affect Disord       Date:  2014-05-04       Impact factor: 4.839

10.  Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design.

Authors:  Madhukar H Trivedi; Patrick J McGrath; Maurizio Fava; Ramin V Parsey; Benji T Kurian; Mary L Phillips; Maria A Oquendo; Gerard Bruder; Diego Pizzagalli; Marisa Toups; Crystal Cooper; Phil Adams; Sarah Weyandt; David W Morris; Bruce D Grannemann; R Todd Ogden; Randy Buckner; Melvin McInnis; Helena C Kraemer; Eva Petkova; Thomas J Carmody; Myrna M Weissman
Journal:  J Psychiatr Res       Date:  2016-03-15       Impact factor: 4.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.